Summary
Jonas Salk (1914—1995) was an American virologist who developed the first effective polio vaccine, tested in the largest field trial in American history and announced on April 12, 1955. The son of Jewish immigrants in the East Bronx, Salk built his career despite anti-Semitic hiring barriers, working outside the established academic hierarchy at the University of Pittsburgh. His killed-virus approach was contested by the majority of virologists, including Albert Sabin, yet it proved sound. The NFIP’s media apparatus transformed him into a celebrity-scientist without precedent, a status that permanently estranged him from his professional peers. Late in life he pursued an AIDS vaccine through a for-profit corporation, returned to California, and died in 1995 without the reconciliation with Sabin he never sought.
Life and Formation
Salk grew up in poverty in the East Bronx, the son of Jewish immigrants with no formal education.(Oshinsky, 2005) He entered NYU Medical School at fifteen.(Oshinsky, 2005) His scientific worldview was shaped by his mentor Thomas Francis Jr., who pioneered killed-virus influenza vaccine research and taught Salk that inactivated viruses could produce durable immunity.(Oshinsky, 2005)
Anti-Semitism constrained Salk’s academic career.(Oshinsky, 2005) Despite strong credentials, he was denied a faculty position at NYU because Jewish academics faced institutional discrimination.(Oshinsky, 2005) He ended up at the University of Pittsburgh, then a third-tier medical school.(Oshinsky, 2005)
By the late 1940s, three researchers were simultaneously pursuing polio vaccines: Salk, Sabin, and Hilary Koprowski.(Oshinsky, 2005) The NFIP had funded a $1.37 million typing program using 17,500 monkeys to classify poliovirus strains; Salk used the tedium of that program as a vehicle to develop his own vaccine approach.(Oshinsky, 2005) The institutional arrangement that resulted was historically unusual: a relationship of mutual dependence between a philanthropic funder and a single researcher, in which the NFIP’s fortunes became tied to Salk’s progress.(Oshinsky, 2005)
The Killed-Virus Gamble
In the early 1950s, the dominant view among virologists was that durable immunity required infection with a live, weakened virus. A killed-virus vaccine, most experts believed, could produce only temporary protection at best.(Oshinsky, 2005) Albert Sabin, Salk’s principal rival, held this position with particular conviction and made no secret of his contempt for Salk’s approach.(Oshinsky, 2005)
Salk’s innovation was to combine the Enders tissue culture technique with a systematic killed-virus protocol, inactivating three strains of poliovirus with carefully calibrated formaldehyde treatment.(Oshinsky, 2005) He made one decision that other researchers considered reckless: choosing the Mahoney strain for Type I poliovirus, the most virulent available, on the theory that the strongest antigen would produce the strongest immune response.(Oshinsky, 2005)
Dorothy Horstmann’s 1952 discovery that poliovirus traveled through the bloodstream before reaching the nervous system provided the theoretical justification Salk needed. If the virus had a bloodstream phase, circulating antibodies from a killed-virus vaccine could intercept it before it caused paralysis.(Oshinsky, 2005) His early results showed antibody levels comparable to those following natural infection.(Oshinsky, 2005)
At the January 1953 Hershey meeting of the NFIP Immunization Committee, Salk presented preliminary data from trials at the Watson Home and Polk School. Sabin dismissed the data as preliminary; John Enders called for more animal testing; the committee declined to endorse field trials.(Oshinsky, 2005) The NFIP awarded Salk its largest grant, $255,472, and his laboratory expanded to seven technicians and a 500-monkey colony.(Oshinsky, 2005) A letter advised against being pushed into premature field tests and urged waiting until everything was carefully worked out before proceeding on a public scale.(Oshinsky, 2005)
Merthiolate, a preservative imposed on the vaccine formulation by the National Institutes of Health over Salk’s explicit objections, reduced the potency of the preparation used in the 1954 field trial. Salk later estimated that without it, “the field trial would have been close to 100% effective.”(Oshinsky, 2005)
Early Trials and Ethical Questions
Salk’s first human trial in 1952 used institutionalized residents of the D.T. Watson Home for Crippled Children, children who had already had polio and thus faced no risk of new infection from the vaccine itself.(Oshinsky, 2005) The choice of institutionalized disabled children as research subjects illustrates the ethical norms of mid-century medical research, norms that permitted practices later generations would reject.(Oshinsky, 2005)
Salk vaccinated his own wife and three sons with the experimental vaccine before any large-scale trial, a gesture of personal conviction that became central to his public image.(Oshinsky, 2005) He argued publicly that using placebo injections in the field trial was morally unacceptable, but the trial proceeded with a double-blind placebo-controlled design in some counties alongside an observed-control design in others, creating what Oshinsky describes as two simultaneous experiments involving 1.5 million children.(Oshinsky, 2005)(Oshinsky, 2005)
The 1954 Field Trial
The 1952 epidemic had been the worst in American history: 57,628 cases and 3,145 deaths in a single year.(Oshinsky, 2005) [GAP: missing citation for claim that social pressure was proportionate to the scale of the epidemic] Thomas Francis Jr. agreed to direct the independent Vaccine Evaluation Center at the University of Michigan after negotiating complete independence from the NFIP, including control over data, study design, and timing of any announcement.(Oshinsky, 2005)
The 1954 field trial was the largest controlled public health experiment in American history. Approximately 1.8 million children participated; 650,000 were actually vaccinated.(Oshinsky, 2005) The logistical scale required the cooperation of schools, parents, public health officials, and hundreds of thousands of volunteer administrators across the country. Its ambition was not merely scientific: the NFIP, which had organized March of Dimes fundraising for two decades, was also staging a demonstration of what private philanthropy and mass civic participation could accomplish.
Celebrity and Its Costs
The National Foundation for Infantile Paralysis transformed Salk into a public figure before his results were fully published. His March 1953 CBS radio broadcast, “The Scientist Speaks for Himself,” introduced the vaccine to millions of Americans.(Oshinsky, 2005) The NFIP’s media strategy, orchestrated by Basil O’Connor, made Salk the prototype of the celebrity-scientist, a cultural category that barely existed before polio.(Oshinsky, 2005)
Reporter John Troan named Salk publicly in the Pittsburgh Press, triggering a wave of celebrity coverage before any peer-reviewed publication had appeared.(Oshinsky, 2005) The NFIP blocked senior virologists including Sabin and John Enders from an early briefing, ensuring no dissenting voices reached the press.(Oshinsky, 2005) Julius Youngner, Salk’s top laboratory assistant, later accused him of claiming first authorship on a paper Youngner had written.(Oshinsky, 2005) Tom Rivers endorsed Salk’s vaccine publicly despite private reservations, illustrating the gap between institutional messaging and scientific candor that characterized the entire campaign.(Oshinsky, 2005)
Harry Weaver, the NFIP’s director of research, championed Salk’s work within the foundation and personally drove the push toward field trials.(Oshinsky, 2005) O’Connor kept certain individuals off the Vaccine Advisory Committee and moved forward with determining how and when to mass‑test the Salk vaccine.(Oshinsky, 2005) A new committee was formed to break a logjam, as Harry Weaver admitted, because the Immunization Committee was too slow, became entangled in technical debates, and its virologist members could not address non‑virological decisions.(Oshinsky, 2005) Within the research community, Albert Sabin was widely viewed as believing polio research to be a zero‑sum game, with no room for two successful vaccines.(Oshinsky, 2005)
April 12, 1955
Thomas Francis Jr. announced his findings at the University of Michigan on April 12, 1955, a date chosen as the tenth anniversary of Franklin Roosevelt’s death. Francis declared the vaccine “safe, effective, and potent,” with efficacy ranging from 60 to 90 percent depending on poliovirus type.(Oshinsky, 2005) Salk immediately claimed that his improved 1955 formulation was already superior to what had been tested, effectively upstaging Francis at his own event.(Oshinsky, 2005)
The announcement triggered reactions likened to V-J Day: church bells rang, factory whistles sounded, and people wept in the streets.(Oshinsky, 2005) In an appearance on Edward R. Murrow’s television program “See It Now,” Salk was asked who owned the patent on the vaccine and replied, “Could you patent the sun?”, a phrase that became iconic; the exchange was described as one of the most celebrated moments in the history of American science.(Oshinsky, 2005)
The Cutter Incident
Julius Youngner warned Salk before the vaccine’s release that the filtration protocols were not adequate to prevent clumping, but Salk dismissed the concern; Youngner later described learning of the Cutter cases as one of the most horrifying moments of his professional life.(Oshinsky, 2005)
Displacement by Sabin
By 1963, Albert Sabin’s oral poliovirus vaccine had largely supplanted Salk’s injectable formulation in American public health practice.(Oshinsky, 2005) Oshinsky describes this displacement as a professional humiliation that Salk never accepted.(Oshinsky, 2005)
The Salk Institute and Later Career
Salk left the University of Pittsburgh following conflicts with Chancellor Edward Litchfield over the governance of his laboratory. He divorced his first wife, Donna, in 1968 and married the French painter Françoise Gilot in 1970.(Oshinsky, 2005) He relocated to La Jolla, California, where the Salk Institute for Biological Studies, designed by architect Louis Kahn and opened in 1963, had been built as what Salk described as a “temple of Zeus” for scientists and humanists to work together.(Oshinsky, 2005)
In the late years of his career, Salk pursued an AIDS vaccine through the Immune Response Corporation, a for-profit venture. He accepted approximately $3 million in stock in the company before clinical trials had established efficacy, a conflict of interest that was noted by critics within the research community.(Oshinsky, 2005) In 1993, at a ceremony marking the fortieth anniversary of the polio vaccine’s development, Julius Youngner publicly accused Salk of having taken sole credit for work that others in the laboratory had performed.(Oshinsky, 2005)
Death and Posthumous Vindication
Jonas Salk died on June 23, 1995, of heart failure. Albert Sabin had died on March 3, 1993. The two men never reconciled; the rivalry that defined their careers ended as it had lived, unresolved.(Oshinsky, 2005)
The vindication of Salk’s approach was a product of his rival’s success rather than his failure. In 2000, the Centers for Disease Control reinstated the killed-virus injectable vaccine as the exclusive recommended formulation for American children. The reason was specific: wild poliovirus had been eliminated from the Western Hemisphere, which meant that the only remaining polio cases in the United States were caused by the Sabin vaccine’s live attenuated virus, at an estimated rate of approximately one case per 750,000 first doses. Where the wild virus was absent, the oral vaccine’s advantages disappeared and the residual risk of vaccine-associated paralytic polio remained.(Oshinsky, 2005) Policy had come full circle, though no ceremony marked it.
Scholarly Assessment
Oshinsky’s account of Salk is distinguished by its refusal to separate the institutional from the personal. In Polio: An American Story, the vaccine campaign is not a triumph-of-science narrative but a human drama in which ambitions, institutional allegiances, and competitive pressures are inseparable from the scientific decisions that mattered, including choice of virus strain, trial design, and the timing of public communication.
Salk emerges from Oshinsky’s account as a figure whose scientific judgment was substantially vindicated and whose character was persistently problematic. The killed-virus approach worked, the field trial was sound, and the April 12 announcement was accurate. At the same time, the credit disputes within his laboratory were real; the upstaging of Francis at the Ann Arbor announcement was a public act of ingratitude; and the AIDS vaccine venture, with its stock arrangement before proof of efficacy, illustrated a willingness to blur the line between scientific and financial interest. These are not isolated events. They form a pattern consistent with what his colleagues described from the beginning: a man who understood institutional power, cultivated public attention, and used both in ways that left lasting resentments.
What Oshinsky does not do is reduce Salk to a caricature. The scientific case for his approach was legitimate and ultimately correct. The public communication, however much it served the NFIP’s fundraising and his own celebrity, reached millions of Americans at a moment when the 1952 epidemic, the worst in American history, had made parents desperate for reliable information. The life’s work held together. The man behind it was harder to assess cleanly.